Outcomes and Quality of Life Issues in the Pharmacological Management of Benign Prostatic Hyperplasia (BPH)

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2008 Mar 25

PMID 18360626

Citations 4

Authors

Angelo J Cambio

Christopher P Evans

Affiliations

Soon will be listed here.

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common disease of the aging male population. BPH treatment includes a variety of pharmacological and surgical interventions. The goal of this paper is to review the natural history of BPH, outcomes of pharmacological management, effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused perspectives.

Materials And Methods: Medline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. Relevant literature was reviewed and analyzed.

Results: Alpha blockers, 5 alpha-reductase inhibitors, and phytotherapy are the three categories of pharmaceutical interventions currently available for BPH. Various clinical trials have shown that alpha blockers and 5 alpha-reductase inhibitors are safe, efficacious, and improve QoL in patients with BPH. The evidence for phytotherapeutics is not as convincing. The current armamentarium of pharmaceutical interventions are encompassed in these three classes of medications. New pharmacotherapies based on novel mechanisms are on the horizon.

Conclusion: There are a variety of safe and efficacious medical therapies available for the management of BPH and it is important for the practicing physician to have an understanding of these pharmacotherapies and their potential impact on the patient. There is not enough evidence to make a recommendation regarding phytotherapy use. New classes of drugs for BPH will likely find their way into routine use.

Citing Articles

Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review.

Abubakar M, Prasad R, Salim S, Basavaraju D, Khan M, Lateef I Cureus. 2023; 15(8):e44097.

PMID: 37750139 PMC: 10518119. DOI: 10.7759/cureus.44097.

Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.

Leoci R, Aiudi G, Silvestre F, Lissner E, Lacalandra G Prostate. 2014; 74(11):1132-41.

PMID: 24913937 PMC: 4145661. DOI: 10.1002/pros.22829.

Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia.

Hadi N, Aminsharifi A, Sadeghi A, Tourchi A Qual Life Res. 2012; 22(6):1287-93.

PMID: 22948258 DOI: 10.1007/s11136-012-0259-7.

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.

Djavan B, Dianat S, Kazzazi A Patient Relat Outcome Meas. 2012; 2:71-9.

PMID: 22915969 PMC: 3417924. DOI: 10.2147/PROM.S13062.

References

Schulman C, Lock T, Buzelin J, Boeminghaus F, Stephenson T, Talja M . Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001; 166(4):1358-63. View

Roberts R, Lieber M, Jacobson D, Girman C, Jacobsen S . Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc. 2005; 80(6):759-64. DOI: 10.1016/S0025-6196(11)61530-9. View

Andersson K, Chapple C, Hofner K . Future drugs for the treatment of benign prostatic hyperplasia. World J Urol. 2002; 19(6):436-42. DOI: 10.1007/s00345-002-0253-8. View

Fong Y, Milani S, Djavan B . Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol. 2004; 15(1):45-8. DOI: 10.1097/00042307-200501000-00011. View

Stachon A, Schluter T, Junker K, Knopf H, Neuser R, Krieg M . The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor. Growth Factors. 2004; 22(4):281-9. DOI: 10.1080/08977190400004835. View

Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G . Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995; 288(2):201-7. DOI: 10.1016/0922-4106(95)90195-7. View

Kirby R, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary M . Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003; 61(1):119-26. DOI: 10.1016/s0090-4295(02)02114-3. View

Abrams P, Schulman C, VAAGE S . Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995; 76(3):325-36. DOI: 10.1111/j.1464-410x.1995.tb07709.x. View

MacDonald R, Wilt T . Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 2005; 66(4):780-8. DOI: 10.1016/j.urology.2005.05.001. View

10.

Bruskewitz R, Girman C, Fowler J, RIGBY O, Sullivan M, Bracken R . Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999; 54(4):670-8. DOI: 10.1016/s0090-4295(99)00209-5. View

11.

Guay D . Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004; 2(1):14-23. DOI: 10.1016/s1543-5946(04)90003-7. View

12.

OLeary M, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K . Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003; 92(3):262-6. DOI: 10.1046/j.1464-410x.2003.04310.x. View

13.

Chung M, Vashi V, Puente J, Sweeney M, Meredith P . Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999; 48(5):678-87. PMC: 2014349. DOI: 10.1046/j.1365-2125.1999.00067.x. View

14.

McAlister F, Laupacis A, Wells G, Sackett D . Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999; 282(14):1371-7. DOI: 10.1001/jama.282.14.1371. View

15.

Fong Y, Milani S, Djavan B . Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol. 2004; 15(1):35-8. DOI: 10.1097/00042307-200501000-00009. View

16.

Coffey D, Walsh P . Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am. 1990; 17(3):461-75. View

17.

Kirby R . Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand J Urol Nephrol Suppl. 1995; 168:29-33. View

18.

Nordling J . Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005; 95(7):1006-12. DOI: 10.1111/j.1464-410X.2005.05456.x. View

19.

Caine M, Perlberg S, Meretyk S . A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978; 50(7):551-4. DOI: 10.1111/j.1464-410x.1978.tb06210.x. View

20.

GILLENWATER J, Conn R, Chrysant S, Roy J, Gaffney M, Ice K . Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995; 154(1):110-15. View